INTRODUCING MANHATTAN PROJECT

For generations, inherited disease shaped our fate. Now in 2025, with advances in genomics, we glimpse into a different future: one where we can correct disease-causing mutations before a child is born.

Manhattan Project was founded to end genetic disease and alleviate human suffering. Using advanced gene correction tools, we aim to fix harmful mutations at the earliest stage of development: when the embryo is still a single cell. At this moment, just after sperm and egg combine, we have a unique opportunity to correct harmful mutations and prevent inherited diseases safely, efficiently, and affordably.

While billions are spent on gene therapies that struggle to reach specific cells in the body, a simpler path lies ahead: correcting the mutation before the complexity of the multicellular organism develops.

Imagine a world where no child inherits a disease-causing mutation. Where one precise change means a lifetime of health.

This is not science fiction, it is science. And we must not fear it. We must not turn away from these questions because they are hard. We must lean in, with transparency, responsible regulation, and scientific rigor.

We are led by a team of scientists and entrepreneurs including Cathy Tie (serial biotech entrepreneur) and Eriona Hysolli, Ph.D. (former Head of Biological Sciences at Colossal, former postdoctoral fellow in the laboratory of George Church), and are backed by visionary institutional investors who share our belief in responsible innovation.

We welcome lead scientists and bioethicists who are motivated by the same goal: to reduce suffering across the world and do it cost-effectively. If you're interested in sponsored research, co-publishing, or joining our team to build the next generation of medicine, reach out.

Manhattan Project is here to bring advancement to biology, justice to inheritance, and health to generations yet to come.

Contact us at info@manhattangenomics.com